Key risks
- Revenue declined 12% quarter-on-quarter from ₹161.17 Cr (Jun 2024) to ₹141.52 Cr (Mar 2025); verify whether company-specific stress or broader sector headwind
- Operating margin thin at 6.34%; limited buffer against raw-material cost spikes or pricing pressure in specialty chemicals
- Stock down 34% over 1y (range ₹57.74–₹118.35); verify underlying business deterioration versus market sentiment shift
- ROE unavailable and virtually no institutional holding (FII 0%, DII 0.38%) signal minimal analyst coverage or investor confidence
Generated analysis · source review pending